Contact the Editorial Desk
Correspondence on citations, corrections, and research-related questions — the feedback a data-forward desk most wants to receive.
Editorial correspondence
Vyra Peptides welcomes mail about the research record: a citation quoted inaccurately, an effect size or confidence interval corrected in an erratum, a regulatory status that has changed (say, if retatrutide reaches approval or a WADA classification), or a peer-reviewed study on tesamorelin or retatrutide that belongs on the references page.
Corrections that improve accuracy are the most useful notes this desk gets. The most actionable ones name the page, quote the exact passage, and give a supporting DOI or PubMed ID, so the change can be checked against the primary source quickly.
Editorial mailbox: editors@vyrapeptides.com
What this desk cannot do
A few requests fall outside what a scorecard is — not from indifference, but because they aren't what this desk does:
- Advise on, recommend, or comment on human use of tesamorelin or retatrutide for any purpose.
- Name a dose, schedule, reconstitution method, or route for any individual.
- Diagnose a condition or judge whether a finding fits a particular person's situation.
- Sell, source, recommend, or help locate either compound from any supplier or vendor.
- Comment on gray-market retatrutide sellers, vendors, or products.
- Advise athletes on anti-doping compliance, tesamorelin being WADA-prohibited.
Readers seeking clinical guidance should consult a licensed clinician in their own jurisdiction. Replies to editorial mail aren't guaranteed and may be delayed; the box is checked on a non-urgent schedule.